; and (G) public and private insurance markets. (b) Authorization of appropriations To carry out this section, there is authorized to be appropriated $3,000,000 for fiscal year 2024. (c) Requirements In conducting the study pursuant to subsection (a), the National Academies shall hold not fewer than 2 public listening sessions to solicit feedback from interested parties, including representatives of academia, professional societies, patient advocates, public health organizations, relevant Federal departments and agencies, drug developers, representatives of other relevant industries, and subject matter experts. (d) Report Not later than 2 years after the date of enactment of this Act, the National Academies shall submit to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives a report on the study conducted pursuant to subsection (a). IV Strengthening biosecurity 401. Treatment of genetic variants and synthetic products of select agents and toxins Section 351A(a)(1) of the Public Health Service Act ( 42 U.S.C. 262a(a)(1) ) is amended by adding at the end the following: (C) Inclusions (i) In general For purposes of the list under this paragraph, the following shall be considered to be a biological agent or toxin included on the list: (I) Any biological agent that incorporates nucleic acids coding for a virulence factor from a listed agent or toxin. (II) Any biological agent or toxin that is genetically homologous to a listed agent or toxin with respect to nucleotides coding for virulence factors or toxicity. (III) Any biological agent or toxin that is synthetically derived with virulence or toxicity characteristics of a listed agent or toxin. (IV) Any nucleic acid that encodes for components contributing to pathogenicity, transmissibility, or toxicity of a listed agent or toxin. (ii) Exemptions The Secretary may exempt from inclusion on the list under this